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Immune evasionwn to disrupt Jak-STAT signal transduction induced by interferon (IFN) through
two distinct mechanisms: (1) secreted poxviral IFN decoy receptors that prevent the initiation of IFN
signaling from type I or II receptors at the cell surface; and (2) poxviral phosphatase that dephosphorylates
STAT1 intracellularly. Here, we report a novel mechanism by which poxviruses can inhibit Jak-STAT signaling
in response to type I IFN. Myxoma virus (MV) is a highly species-restricted member of the poxvirus family
that infects only rabbits under the natural setting. Interestingly, primary human ﬁbroblasts support a
permissive MV infection that is only partially sensitive to the antiviral state induced by type I IFN. In this
study we show that when type I IFN is added to primary human ﬁbroblasts following MV infection, the
tyrosine phosphorylation of the Janus kinase Tyk2 is speciﬁcally blocked, thereby preventing the subsequent
activation of downstream STAT1 and STAT2. In stark contrast, type II IFN-induced activation of Jak1, Jak2
and STAT1 remains largely unaffected in MV-infected human ﬁbroblasts. Unlike the de-activation of
STAT1 by the poxvirus phosphatase, which is delivered into the cell by the input virions, the Tyk2 inhibition
by MV infection requires new viral gene expression. Thus, our study documents a previously unrecognized
immune evasion mechanism exploited by a poxvirus to selectively disrupt the type I IFN-Jak-STAT signaling
cascade.
© 2009 Elsevier Inc. All rights reserved.Introduction
Interferons (IFN), mainly type I (IFN-α/β) and type II IFN (IFN-γ),
are part of a powerful ancient defense system that enables multi-
cellular organisms to combat invading viruses (Hengel et al., 2005;
Sen, 2001; Takaoka and Yanai, 2006). Binding of type I IFN to its cell
surface IFN-α receptor (IFNAR) triggers tyrosine phosphorylation of
the Janus kinases Tyk2 and Jak1 followed by tyrosine phosphorylation
of the transcription factors STAT1 and STAT2. The activated STAT1 and
STAT2 heterodimerize and together with IFN-regulatory factor 9 (IRF-
9) migrate to the nucleus to activate the transcription of IFN-
stimulated genes (ISGs) through the IFN-stimulated responsive
element (ISRE) (Stark et al., 1998; Takaoka and Yanai, 2006). On the
other hand, binding of type II IFN to its cell surface IFN-γ receptor
(IFNGR) activates Jak1 and Jak2 resulting in the tyrosine phosphory-
lation of only STAT1, but not STAT2. As a result, the tyrosine phos-
phorylated STAT1 homodimerizes and migrates to the nucleus tonetics and Microbiology, Uni-
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ll rights reserved.trigger ISG transcription through the γ-activated sequence (GAS)
(Samuel, 2001; Stark et al., 1998). Thus, the signal transduction of type
I versus type II IFN is mediated distinctly through IFNAR-Tyk2/Jak1-
STAT1/STAT2/IRF9-ISRE and IFNGR-Jak1/Jak2-STAT1-GAS, respec-
tively. Consequently, the expression of multiple ISG products such as
ISG15, myxovirus resistance (Mx) and 2′–5′-oligoadenylate synthe-
tase (OAS) leads to the establishment of an antiviral state (Katze et al.,
2002; Randall and Goodbourn, 2008; Samuel, 2001; Stetson and
Medzhitov, 2006).
Given that host immune defenses have co-evolved with viruses
(Hengel et al., 2005; Levy and Garcia-Sastre, 2001), all viruses are likely
to have evolved at least some countermeasures to block the IFN-Jak-
STAT defense pathway as part of their survival strategies (Takaoka and
Yanai, 2006; Weber et al., 2004). For example, herpes simplex virus 1
downregulates the expression of the cell surface receptors IFNAR and
IFNGR (Chee and Roizman, 2004; Eisemann et al., 2008). Downstream
of the IFN receptors, Japanese encephalitis virus and West Nile virus
inhibit Tyk2 and Jak1 tyrosine phosphorylation (Guo et al., 2005; Lin et
al., 2004) while human cytomegalovirus and adenovirus decrease Jak1
expression (Miller et al., 1999; Shi et al., 2007). Further downstream of
the cascade, simian virus 5 and human parainﬂuenza virus type 2 have
been shown to target STAT1 and STAT2 for proteasomal degradation,
respectively (Andrejeva et al., 2002). In addition, while human
Fig. 1. MV infection inhibits type I IFN-induced antiviral ISG expression in primary
human ﬁbroblasts. (A) CCD-922Sk ﬁbroblasts were stimulated with IFN-αC for 4 h and
the total cellular RNA was then isolated for ISG induction proﬁling using the IFN-α/β
response cDNA SuperArray. The ISGs upregulated by IFN-αC are circumscribed in red
lines. (B) CCD-922Sk ﬁbroblasts were infected with MV for 6 h; subsequently, the MV-
infected cells were stimulated with IFN-αC for 4 h. The total cellular RNA was then
isolated for RT-PCR analysis of the mRNAs of MxA and OAS (isoform 1). GAPDH was
used as control.
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rylation of STAT1 and STAT2 (Dinwiddie and Harrod, 2008; Takeuchi
et al., 2003), rabies virus phosphoprotein P and Ebola virus block the
nuclear translocation of tyrosine phosphorylated STAT1 and STAT2
(Brzozka et al., 2006; Reid et al., 2006). In view of the power of such
evolutionary pressures, these instances appear to further emphasize
the notion that the IFN-Jak-STAT signaling cascade is a critical interface
that hosts and viruses are constantly competing to dominate.
Myxoma virus (MV) is the causative agent of a deadly veterinary
disease known as myxomatosis, speciﬁcally in the European rabbit
(Fenner and Ratcliffe, 1965; Kerr and McFadden, 2002). Interest-
ingly, recent work shows that MV not only productively infects
primary human ﬁbroblasts, but also is partially resistant to the
antiviral state induced by type I IFN, while it is fully inhibited by
type I IFN plus TNF (Wang et al., 2008). However, little is known
about how the IFN-Jak-STAT signaling cascade that induces the
antiviral state might be perturbed by MV infection. MV is a poxvirus
and member of the leporipoxvirus genus (Moss, 2001). Containing
large DNA genomes, the poxvirus family members all encode a
unique repertoire of immune evasion molecules that systematically
subvert key host immune defenses, including chemokine, inter-
leukin, complement, apoptosis and Toll-like receptor signaling
(Seet et al., 2003). In particular, poxviruses have been shown to
antagonize a wide range of IFN-induced antiviral ISGs. For example,
vaccinia virus E3L inhibits the antiviral functions of protein kinase R
(PKR), OAS (Katze et al., 2002; Seet et al., 2003) and ISG15 (Guerra
et al., 2008), thus showing a multi-pronged immune evasion
property for the poxvirus family. However, in terms of subversion
of the IFN-Jak-STAT signaling cascade itself, only two distinctly
different mechanisms have been described thus far for the poxvirus
family. In the ﬁrst, poxviruses including MV, vaccinia virus,
ectromelia virus and camelpox virus express soluble IFN receptor
homologs, which act to scavenge IFN ligands and thereby prevent
the initiation of IFN signal transduction at the cell surface (Randall
and Goodbourn, 2008). In the second, a dual speciﬁcity phospha-
tase, such as the vaccinia VH1 protein, dephosphorylates STAT1
following type II IFN stimulation (Najarro et al., 2001) or both STAT1
and STAT2 following type I IFN treatment (Mann et al., 2008),
thereby blocking the IFN-transduced signal at the intracellular STAT
level. However, it remains to be demonstrated how other evasion
strategies would be employed by the poxvirus family members to
subvert the IFN-Jak-STAT pathway following IFN ligation with its
receptors at the cell surface.
Here we show that in primary human ﬁbroblasts, MV infection
blocks type I IFN-induced tyrosine phosphorylation of the upstream
Janus kinase Tyk2, thereby preventing the activation of its down-
stream transcription factors STAT1 and STAT2. In contrast, type II IFN-
induced tyrosine phosphorylation of Jak1, Jak2 and STAT1 is not
signiﬁcantly affected. Thus, we report a novel poxvirus immune
subversion mechanism to selectively disrupt the type I IFN-Jak-STAT
signaling cascade in virus-infected cells.
Results
MV infection inhibits antiviral ISG expression induced by exogenous
type I IFN in primary human ﬁbroblasts
MV infection has been shown to be partially resistant to the
antiviral state induced by type I IFN in CCD-922Sk primary human skin
ﬁbroblasts (Wang et al., 2008). Therefore, we began by deﬁning the
type I IFN responsiveness of CCD-922Sk ﬁbroblasts. To this end, we
stimulated the cells for 4 h with IFN-αC, a member of the type I IFN
family, and isolated total cellular RNA in order to analyze ISG
expression by use of the IFN-α/β response cDNA SuperArray. We
observed that, of the total of 96 genes included in the SuperArray
format, 50 genes were upregulated by IFN-αC (Fig. 1A and Table 1). Inparticular, we noted that the typical antiviral ISGs, such as ISG15, MxA
and OAS, were clearly induced following IFN-αC stimulation (Table 1).
These results indicate that CCD-922Sk ﬁbroblasts per se are capable of
mounting the expected type I IFN responses. Importantly, these data
imply that MV's partial resistance to type I IFN might be related to the
MV inhibition of type I IFN-induced antiviral signaling in CCD-922Sk
cells.
To ascertain whether ongoing MV infection might inhibit the
antiviral ISG response induced by subsequent exposure to type I IFN,
we infected CCD-922Sk ﬁbroblasts with MV for 6 h and then sti-
mulated the infected cells with IFN-αC for 4 h. We then isolated total
cellular RNA and employed RT-PCR to analyze the induction of genes
MxA and OAS, which were chosen here for the purpose of repre-
senting the classical IFN-induced antiviral signaling response (Samuel,
2001). As shown in Fig. 1B, IFN-αC strongly upregulated mRNA
expression of MxA (top panel, lane 3) and OAS (middle panel, lane 3)
in mock-infected cells. In contrast, the same IFN-αC treatment was
unable to induce MxA (Fig. 1B, top panel, lane 4) and OAS (Fig. 1B,
middle panel, lane 4) mRNA expression followingMV infection. Similar
results were obtained from other adult and fetal primary human
ﬁbroblasts (data not shown). Collectively, these results show that MV
infection inhibits the type I IFN-induced antiviral ISG expression in
primary human ﬁbroblasts.
Table 1
Genes upregulated by IFN-αC in primary human ﬁbroblasts
Array position GenBank
access No.
Gene
symbol
Expression
fold increase
A3 NM_012068 AFT5 1.60
A5 NM_004281 BAG3 7.40
A7 NM_006820 IFI44L 333.84
B3 NM_001755 CBFB 2.67
B4 NM_004064 CDKN1B 2.77
B5 NM_033133 CNP 11.11
C2 NM_006736 DNAJB2 5.02
C3 NM_006304 SHFM1 2.32
C4 NM_005101 ISG15 32.12
C5 NM_002038 G1P3 33.54
C6 NM_002053 GBP1 4.96
C7 NM_004120 GBP2 3.07
C8 NM_000161 GCH1 8.78
D1 NM_002196 H19 8.30
D2 NM_002116 HLA-A 3.99
D3 NM_005514 HLA-B 4.22
D4 NM_002145 HOXB2 2.29
D6 NM_005531 IFI16 4.47
D7 NM_005532 ISG12 77.84
D8 NM_006332 IFI30 34.60
E1 NM_005533 IFI35 21.76
E2 NM_006417 IFI44 21.98
E3 NM_001548 IFIT1 106.15
E4 NM_001547 IFIT2 367.94
E5 NM_001549 IFIT3 55.32
E7 NM_003641 IFITM1 6.35
E8 NM_006435 IFITM2 8.70
F2 NM_000629 IFNAR1 4.12
F8 NM_006764 IRFD2 5.44
G3 NM_002199 IRF2 2.75
G6 NM_001572 IRF7 6.20
G8 NM_006084 IRF9 3.01
H3 NM_017554 PARP14 14.55
H4 NM_001648 KLK3 11.58
H5 NM_005561 LAMP1 2.79
I1 NM_020310 MNT 5.13
I2 NM_002462 MXA 2.18
I3 NM_002463 MX2 49.36
I4 NM_002467 MYC 1.88
I5 NM_002468 MYD88 3.17
I8 NM_002534 OAS1 21.58
J1 NM_002535 OAS2 32.26
J2 NM_003733 OASL 6.67
J6 NM_003690 PRKRA 1.68
J8 NM_002818 PSME2 4.84
L1 NM_005419 STAT2 2.11
L3 NM_003810 TNFSF10 44.08
L5 NM_006074 TRIM22 4.36
L6 NM_021616 TRIM34 3.87
L7 NM_003331 TYK2 5.48
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in primary human ﬁbroblasts
The inhibition of type I IFN-induced expression of antiviral ISGs
in MV-infected CCD-922Sk ﬁbroblasts led us to ﬁrst focus on STAT1,
a primary mediator involved in mounting the IFN antiviral signaling
response (Randall and Goodbourn, 2008; Takaoka and Yanai, 2006).
To ascertain whether or not MV infection inhibited STAT1 nuclear
translocation, a hallmark feature of STAT1 activation (Randall and
Goodbourn, 2008; Samuel, 2001), we infected CCD-922Sk ﬁbro-
blasts with MV for 6 h and then treated the MV-infected cells with
IFN-αC for 30 min. We employed immunoﬂuorescence microscopy
to assess the nuclear accumulation of STAT1 at the single cell level.
As expected, STAT1 was distributed predominantly in the cytoplasm
under the basal state (Fig. 2, top row), but was overwhelmingly
mobilized to the nucleus after the IFN-αC stimulation in mock-
infected cells (Fig. 2, second row). In contrast, neither MV infection
alone nor IFN-αC treatment of MV-infected cells was able to induce
the translocation of STAT1 into the nucleus in the infected cells(Fig. 2, third and fourth row, respectively). We conﬁrmed MV in-
fection by immunostaining of the infected cell monolayers for the
expression of M-T7, an early MV gene product, as the viral infection
marker (Mossman et al., 1996). We observed that the blockade of
IFN-αC-induced STAT1 nuclear translocation speciﬁcally occurred
in M-T7-positive cells (Fig. 2, fourth row). Thus, this result demons-
trates an unequivocal correlation between MV infection and im-
pairment in the nuclear mobilization of STAT1 following type I IFN
stimulation.
Next, to determine whether or not the MV-mediated inhibition of
STAT1 nuclear translocation was limited to type I IFN, we infected
CCD-922Sk ﬁbroblasts with MV for 6 h and then stimulated the
MV-infected cells with type II IFN for 30 min. As shown in Fig. 2 (ﬁfth
row), IFN-γ treatment of mock-infected cells mobilized STAT1 into the
nucleus. However, unlike IFN-αC, this IFN-γ-induced nuclear mobi-
lization of STAT1 was not blocked by MV infection (Fig. 2, bottom
row). Taken in toto, the above results indicate that MV infection
selectively inhibits the STAT1 nuclear translocation induced by type I
but not type II IFN in primary human ﬁbroblasts.
MV infection inhibits type I IFN-induced tyrosine phosphorylation of
STAT1 in primary human ﬁbroblasts
Tyrosine phosphorylation is a key step in STAT1-mediated IFN
signal transduction (Randall and Goodbourn, 2008; Stark et al., 1998).
Therefore, to determine whether or not MV infection suppressed
tyrosine phosphorylation of STAT1, we infected CCD-922Sk ﬁbroblasts
with MV for 6 h and then stimulated the MV-infected cells with IFN-
αC for 30 min. Subsequently, we conducted immunoprecipitation of
STAT1α, a key functional isoform of STAT1 (Stark et al., 1998), out of
the whole cell extracts using an anti-STAT1α antibody. As revealed by
Western blotting using an anti-phosphotyrosine antibody, IFN-αC
treatment resulted in a strong band of STAT1 tyrosine phosphorylation
in mock-infected cells (Fig. 3A, top left panel, lane 3). In contrast, the
same IFN-αC treatment failed to induce STAT1 tyrosine phosphoryla-
tion in MV-infected cells (Fig. 3A, top left panel, lane 4). We then
examined the impact of MV infection on STAT1 tyrosine phosphoryla-
tion following IFN-γ stimulation. As expected, IFN-γ caused a strong
tyrosine phosphorylation signal in mock-infected cells (Fig. 3A, top
right panel, lane 3). Signiﬁcantly, IFN-γ-induced STAT1 tyrosine
phosphorylation was not inhibited by MV infection (Fig. 3A, top
right panel, lane 4).
Of note, it has been shown that certain viruses, such as measles
virus and Ebola virus, do not suppress IFN-induced STAT1 tyrosine
phosphorylation per se but instead prohibit nuclear translocation of
the tyrosine phosphorylated STAT1 (Palosaari et al., 2003; Reid et al.,
2006). Therefore, we determined the subcellular localization features
of the tyrosine phosphorylated STAT1 induced by IFN-γ in MV-
infected cells. For this purpose, we took advantage of an activation
status-speciﬁc antibody which detects STAT1 only when Tyr-701 is
phosphorylated. As shown by immunoﬂuorescent antibody staining,
tyrosine phosphorylated STAT1 was barely discernable in mock-
infected CCD-922Sk ﬁbroblasts prior to IFN-γ stimulation (Fig. 3B, top
row) whereas a strong immunoﬂuorescence signal for tyrosine
phosphorylated STAT1 was detected in the nucleus following IFN-γ
treatment (Fig. 3B, second row). Of note, MV infection itself did not
cause any tyrosine phosphorylation of STAT1 (Fig. 3B, third row).
Remarkably, the IFN-γ-induced nuclear localization of tyrosine
phosphorylated STAT1 was unaffected by MV infection (Fig. 3B,
bottom row). In contrast, we were unable to detect any immuno-
ﬂuorescence signal for tyrosine phosphorylated STAT1 in either the
nucleus or the cytoplasm of MV-infected cells following IFN-αC
stimulation (data not shown). This is consistent with the Western
blotting data (Fig. 3A, top left panel). Collectively, these results further
demonstrate that MV infection only inhibits STAT1 tyrosine phos-
phorylation initiated by type I IFN but does not interfere with the
Fig. 2.MV infection blocks the STAT1 nuclear translocation induced by type I but not type II IFN in primary human ﬁbroblasts. Mock andMV-infected CCD-922Sk ﬁbroblasts were left
alone or stimulatedwith IFN-αC or IFN-γ for 30min as indicated. Double immunoﬂuorescence staining was conducted to visualize the expression of MV early geneM-T7 (green) and
the subcellular localization of STAT1 protein (red).
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type II IFN.
MV gene expression is required for inhibition of type I IFN-induced
tyrosine phosphorylation of STAT1 in primary human ﬁbroblasts
The inhibition of IFN-induced STAT1 tyrosine phosphorylation by
vaccinia virus through VH1 phosphatase is a rapid, viral dose-
dependent, but viral gene expression-independent process, because
the phosphatase is delivered by the input virions. Thus, infection of
HeLa or 3T3 cells with vaccinia virus at an MOI of 10 for 1 h to allow
for the release of VH1 phosphatase from the virion into the
cytoplasm was sufﬁcient for the inhibitory effect on either type I or
type II IFN signal transduction (Mann et al., 2008; Najarro et al.,
2001). Given that MV I1L (also referred to as M069L) encodes a
phosphatase homologous to vaccinia VH1 phosphatase (Mossman
et al., 1995a), we infected CCD-922Sk ﬁbroblasts with MV at an MOI
of 0.5, 5 and 10 for 1 and 6 h and then challenged the MV-infected
cells with IFN-αC for 30 min. We observed that IFN-αC-induced
tyrosine phosphorylation of STAT1 was not inhibited by MV at 1 h
either at an MOI of 0.5 (Fig. 4A, top panel, lane 4), 5 (Fig. 4A, third
panel, lane 4) or 10 (Fig. 4A, ﬁfth panel, lane 4). However, IFN-αC-
induced tyrosine phosphorylation of STAT1 was fully suppressed in
MV-infected cells at 6 h at either an MOI of 5 (Fig. 4A, third panel,
lane 5) or 10 (Fig. 4A, ﬁfth panel, lane 5). Thus, these late appearing
inhibitory effects imply that the incoming MV virion components
such as I1L phosphatase are unlikely to be responsible for suppres-
sing STAT1 phosphorylation.
Of particular note, Western blot only revealed a minor reduction in
tyrosine phosphorylation of STAT1 in the cells infected with MV at anMOI of 0.5 for 6 h (Fig. 4A, top panel, lane 5). We reasoned that the
observed inefﬁcient suppression of STAT1 tyrosine phosphorylation
under the low MOI infection condition was due to a reduced number
of cells being productively infected. To conﬁrm this, we conducted
immunoﬂuorescent antibody staining for both MV infection marker
M-T7 and tyrosine phosphorylated STAT1. We found that at an MOI of
0.5, roughly one fourth of the cells were infected, as identiﬁed byM-T7
expression (Fig. 4B, second row). As expected, IFN-αC treatment
caused a strong nuclear accumulation of tyrosine phosphorylated
STAT1 (Fig. 4B, third row). Signiﬁcantly, we observed that among the
IFN-αC-treated cell population, only those that expressed M-T7
showed inhibition of immunoﬂuorescent staining for tyrosine phos-
phorylated STAT1 (Fig. 4B, bottom row). These data clearly demon-
strate that MV expresses or induces a strong suppressor of STAT1
tyrosine phosphorylation following type I IFN stimulation in a manner
dependent on MV gene expression.
To examine this further, we prepared UV-inactivated MV that
was no longer able to synthesize signiﬁcant levels of de novo viral
proteins as indicated by the suppression of synthesis of an early MV
protein M-T7 (Fig. 4C, top panel) and was unable to produce
infectious MV progeny (data not shown). We then infected CCD-
922Sk ﬁbroblasts with the UV-inactivated MV for 6 h and stimu-
lated the infected cells with IFN-αC for 30 min. We observed that
unlike replication-competent MV, UV-inactivated MV failed to inhibit
IFN-αC-induced tyrosine phosphorylation of STAT1 (Fig. 4D, top
panel). These data show that MV gene expression is required for the
inhibition of tyrosine phosphorylation of STAT1 in response to type I
IFN.
Next, to further dissect whether early or late MV proteins me-
diate the inhibition of type I IFN signaling, we then performed MV
Fig. 3. MV infection inhibits the STAT1 tyrosine phosphorylation induced by type I but not type II IFN in primary human ﬁbroblasts. (A) Mock and MV-infected CCD-922Sk
ﬁbroblasts were left alone or stimulated with IFN-αC or IFN-γ for 30 min as indicated. The cell lysates were then immunoprecipitated (IP) with anti-STAT1α antibody.
Western blots (WB) were probed with anti-phosphotyrosine (p-Tyr) or anti-STAT1α antibodies. (B) Mock and MV-infected CCD-922Sk ﬁbroblasts were left alone or
stimulated with IFN-γ for 30 min. Double immunoﬂuorescence staining was conducted to visualize the expression of MV early gene M-T7 (green) and the subcellular
localization of tyrosine phosphorylated STAT1 (red).
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blocks viral late gene expression but has no inhibitory impact on
viral early gene expression (Boshkov et al., 1992). We observed that
when MV late gene expression was blocked by AraC, MV infection
failed to completely inhibit IFN-αC-induced tyrosine phospho-
rylation of STAT1 (Fig. 4E, top panel, lane 6). Taken in aggregate,
these data suggest that a full-ﬂedged suppression of type I IFN
signaling by MV infection in primary human ﬁbroblasts requires a
combinatorial action of both MV-encoded early and late gene
products.
MV infection does not inhibit type I IFN binding to cell surface IFN-α
receptor in primary human ﬁbroblasts
The ﬁrst step in IFN signal transduction is the binding of IFN to its
cell surface cognate receptors (Randall and Goodbourn, 2008; Stark
et al., 1998). Although type I and type II IFN transduce through
distinct cell surface receptors, i.e. IFNAR and IFNGR, respectively, both
receptor cascades converge downstream on STAT1 (Samuel, 2001;
Stark et al., 1998). Thus, the inhibition of IFN-αC-induced, but not
IFN-γ-induced, tyrosine phosphorylation of STAT1 in MV-infectedcells suggests that MV infection might mediate a selective block at
the type I IFN–IFNAR binding stage. Functional IFNAR is comprised of
two subunits, IFNAR1 and IFNAR2 (Stark et al., 1998). As a number of
viruses downregulate IFN receptors as a way to subdue IFN antiviral
effects (Chee and Roizman, 2004; Joseph and Look, 2001), we
therefore sought to ﬁrst examine the levels of IFNAR expression. To
this end, we infected CCD-922Sk ﬁbroblasts with MV for 6 h. The
biotin labeling of cell surface proteins was then carried out with
Sulfo-NHS-Biotin. Subsequently, the cell extracts from the biotin-
labeled cells were prepared for the separate evaluation of IFNAR1 and
IFNAR2 by immunoprecipitation utilizing anti-IFNAR1 or anti-IFNAR2
antibodies followed by Western blotting with an HRP-streptavidin
conjugate. As revealed in Fig. 5A, there were no apparent differences
in either IFNAR1 (top panel) or IFNAR2 (middle panel) expression
between mock and MV-infected cells. The speciﬁcity of this cell
surface biotin labeling was conﬁrmed using an intracellular protein
USF2 as a control (Fig. 5A, bottom panel). These data clearly indicate
that MV infection does not modulate cell surface IFN-α receptor
levels in CCD-922Sk ﬁbroblasts.
To further ascertain whether or not MV infection affected the
capacity of the host IFNAR to bind exogenous type I IFN, we then
Fig. 4. MV gene expression is necessary for the inhibition of the STAT1 tyrosine phosphorylation induced by type I IFN in primary human ﬁbroblasts. (A) CCD-922Sk ﬁbroblasts of
mock and MV infections at different MOIs as indicated were left alone or stimulated with IFN-αC for 30 min. The cell lysates were immunoprecipitated (IP) with anti-STAT1α
antibody. Western blots (WB) were probed with anti-phosphotyrosine (p-Tyr) or anti-STAT1α antibodies. (B) CCD-922Sk ﬁbroblasts of mock andMV infection at an MOI of 0.5 were
left alone or stimulated with IFN-αC for 30 min. Double immunoﬂuorescence staining was conducted to visualize the expression of MV early gene M-T7 (green) and the subcellular
localization of tyrosine phosphorylated STAT1 (red). (C) CCD-922Sk ﬁbroblasts were mock-infected or infected with MV or UV-inactivated MV (UV-MV) as indicated and the cell
lysates were immunoblotted for the expression of MV early gene M-T7 using anti-M-T7 antibody. (D) CCD-922Sk ﬁbroblasts of mock and MV or UV-MV infections as indicated were
left alone or stimulated with IFN-αC for 30 min. The cell lysates were then immunoprecipitated (IP) with anti-STAT1α antibody. Western blots (WB) were probed with anti-
phosphotyrosine (p-Tyr) or anti-STAT1α antibodies. (E) CCD-922Sk ﬁbroblasts of mock and MV infections carried out in the absence or presence of AraC as indicated were left alone
or stimulated with IFN-αC for 30 min. The cell lysates were then immunoprecipitated (IP) with anti-STAT1α antibody. Western blots (WB) were probed with anti-phosphotyrosine
(p-Tyr) or anti-STAT1α antibodies.
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IFN-αC. Following the preparation of the cell extracts, immunopre-
cipitation was performed using anti-IFN-α antibody followed by
Western blotting with an HRP-streptavidin conjugate. As shown in Fig.
5B (top panel), comparable levels of IFN-αC were bound to the cell
surface of both mock and MV-infected cells. The detection speciﬁcity
for the biotinylated IFN-αC bound to the cell surface was again tested
by using the intracellular protein USF2 (Fig. 5B, bottom panel). Thus,
these data conﬁrm that the host IFNAR retains the ability to bind
exogenous type I IFN following MV infection. Signiﬁcantly, these
results further suggest that there are no MV-encoded molecules that
would capture additional exogenous type I IFN on the infected cell
surface.
To explore this further, we then sought to determine whether the
impaired tyrosine phosphorylation of STAT1 was caused by the
interference of secreted IFN-binding molecules encoded by infecting
MV in a manner demonstrated for other poxviruses. For instance,
vaccinia virus secretes soluble IFN-α viroreceptors which bind to bothinfected and uninfected cell surface, thereby hindering type I IFN from
binding to the host IFN-α receptors (Alcami et al., 2000). To examine
whether or not this is the case for MV, we infected CCD-922Sk
ﬁbroblasts with MV for 6 h. The MV-conditioned media (MV-CM)was
subsequently transferred to uninfected cells. After the cells were
incubated with MV-CM for 1 h to ensure surface binding by any
potential viral IFN decoy receptors in MV-CM, IFN-αC was added
subsequently for 30min.We observed that MV-CM treatments had no
inhibitory effect on tyrosine phosphorylation of STAT1 following IFN-
αC treatment (Fig. 5C, top panel). To further determine whether MV
encodes any secreted IFN-binding protein(s) that would act mainly in
a free form in the culture medium, we pre-incubated IFN-αC with the
above MV-CM for 1 h. We then transferred the IFN-containing
medium to fresh CCD-922Sk cells for 30 min. We observed that the
IFN-αC pre-incubated with MV-CM invoked tyrosine phosphorylation
of STAT1 as efﬁciently as did with the mock-conditioned medium
(data not shown). Taken together, the above results indicate that MV
is most probably not in a position to encode any type I IFN binding
Fig. 5.MV infection does not affect type I IFN binding to the cell surface IFN-α receptors in primary human ﬁbroblasts. (A) CCD-922Sk ﬁbroblasts were mock or MV-infected for 6 h
and cell surface molecules were biotinylated with Sulpho-NHS-Biotin. The cell lysates were then immunoprecipitated (IP) with anti-IFNAR1 or anti-IFNAR2 antibodies. Western blots
(WB) were probed with a horseradish peroxidase (HRP)-conjugated streptavidin. Immunoprecipitation with the antibody against an intracellular protein USF2 was used as the
negative control. (B) CCD-922Sk ﬁbroblasts were mock or MV-infected for 6 h. Then, biotinylated-IFN-αC was incubated with the cells at 4 °C for 1 h to examine the binding capacity
of the cell surface IFNAR. Subsequently, the cell lysates were immunoprecipitated (IP) with an anti-IFN-α antibody. Western blots (WB) were probed with a horseradish peroxidase
(HRP)-conjugated streptavidin. Immunoprecipitation with the antibody against an intracellular protein USF2 was used as the negative control. (C) CCD-922Sk ﬁbroblasts treated by
mock and MV-conditioned medium (MV-CM) were left alone or stimulated with IFN-αC for 30 min as indicated. The cell lysates were immunoprecipitated (IP) with anti-STAT1α
antibody. Western blots (WB) were probed with anti-phosphotyrosine (p-Tyr) or anti-STAT1α antibodies. (D) CCD-922Sk ﬁbroblasts of mock, WT MV and MV-135KO infections as
indicated were left alone or stimulated with IFN-αC for 30 min. The cell lysates were then immunoprecipitated (IP) with anti-STAT1α antibody. Western blots (WB) were probed
with anti-phosphotyrosine (p-Tyr) or anti-STAT1α antibodies.
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IFN in the human cell culture environment.
Notably, systematic sequence analysis of MV genome has reveled
that there is only one MV gene designated M135R homologous to the
vaccinia virus gene B18R that is known to encode a potent type I IFN
decoy receptor (Alcami et al., 2000; Barrett et al., 2007). Thus, to
formally demonstrate that noMV-encoded type I IFN decoy receptor is
involved in MV-mediated inhibition of type I IFN signaling, we
infected CCD-922Sk ﬁbroblasts for 6 h with both wild type MV and a
recombinant MV in which the M135R gene has been knocked out
(MV-135KO) and then stimulated the infected cells with IFN-αC for
30 min. Signiﬁcantly, we observed that tyrosine phosphorylation of
STAT1 was equally inhibited in both wild type MV and MV-135KO-
infected cells following IFN-αC stimulation (Fig. 5D, lanes 5 and 6).
Taken collectively, our results thus clearly show that in primary
human ﬁbroblasts, MV-mediated blockade of the type I IFN signaling
is not due to the interference by MV-encoded IFN decoy receptor at
the cell surface IFN-α receptor binding stage.
MV infection inhibits type I IFN-induced tyrosine phosphorylation of
Tyk2 in primary human ﬁbroblasts
Type I IFN-induced activation of STAT1 is triggered by tyrosine
phosphorylation of the upstream Janus kinases Tyk2 and Jak1, which
are pre-associated with the cytoplasmic tails of IFNAR1 and IFNAR2,
respectively (Randall and Goodbourn, 2008; Stark et al., 1998). None-
theless, in terms of the requirements for STAT1 activation per se, the
transcription factor STAT2, an essential component of IFN-stimulated
gene factor 3 (ISGF3) complex, must be ﬁrst tyrosine phosphorylated
by the Janus kinases in order to create a docking site so that
subsequent STAT1 tyrosine phosphorylation can occur (Randall andGoodbourn, 2008; Stark et al., 1998). Thus, as a necessary step in
further pinpointing how MV inhibits the type I IFN signaling cascade,
we examined whether or not MV infection caused the suppression of
STAT2 tyrosine phosphorylation. For this purpose, we conducted a
STAT2 immunoprecipitation from the MV-infected CCD-922Sk ﬁbro-
blasts following IFN-αC treatment for 30 min. As expected, IFN-αC
stimulation resulted in strong tyrosine phosphorylation of STAT2 in
mock-infected cells (Fig. 6A, top panel, lane 3). In contrast, IFN-αC-
induced tyrosine phosphorylation of STAT2 was suppressed by MV
infection (Fig. 6A, top panel, lane 4). However, the total protein levels
of STAT2 remained unchanged in both mock and MV-infected cells
(Fig. 6A, bottom panel). Together, these results suggest that the up-
stream Janus kinases are the likely molecular target(s) for MV-
mediated inhibition of the type I IFN signaling.
To further investigate this inference, we stimulated mock and MV-
infected CCD-922Sk ﬁbroblasts with IFN-αC for 15 min and then
examined the tyrosine phosphorylation status of Tyk2 and Jak1. We
observed that IFN-αC treatment induced strong tyrosine phosphor-
ylation of Tyk2 (Fig. 6B, top panel, lane 3) and Jak1 (Fig. 6B, third
panel, lane 3) in mock-infected cells. Signiﬁcantly, MV infection not
only abrogated IFN-αC-induced tyrosine phosphorylation of Tyk2
(Fig. 6B, top panel, lane 4), but also considerably decreased IFN-αC-
induced tyrosine phosphorylation of Jak1 (Fig. 6B, third panel, lane 4).
Nevertheless, the total protein levels of Tyk2 (Fig. 6B, second panel)
and Jak1 (Fig. 6B, fourth panel) were not affected by MV infection.
Furthermore, UV-inactivated MV was unable to inhibit IFN-αC-
induced tyrosine phosphorylation of Tyk2 or Jak1 (data not shown).
Taken collectively, these data compliment the MV-mediated suppres-
sion of IFN-αC-induced tyrosine phosphorylation of STAT1 (Fig. 3A,
top left panel), but would also predict that IFN-γ-induced tyrosine
phosphorylation of STAT1 might be concurrently reduced because
Fig. 6.MV infection abrogates Tyk2 tyrosine phosphorylation induced by type I IFN in primary human ﬁbroblasts. (A) Mock andMV-infected CCD-922Sk ﬁbroblasts were left alone or
stimulated with IFN-αC for 30 min. The cell lysates were immunoprecipitated (IP) with anti-STAT2 antibody. Western blots (WB) were probed with anti-phosphotyrosine (p-Tyr) or
anti-STAT2 antibodies. (B) Mock and MV-infected CCD-922Sk ﬁbroblasts were left alone or stimulated with IFN-αC for 15 min. The cell lysates were immunoprecipitated (IP) with
anti-Tyk2 or anti-Jak1 antibodies. Western blots (WB) were probed with anti-phosphotyrosine (p-Tyr) or anti-Tyk2 or anti-Jak1 antibodies. (C) Mock and MV-infected CCD-922Sk
ﬁbroblasts were left alone or stimulatedwith IFN-γ for 15min. The cell lysateswere immunoprecipitated (IP) with anti-Jak1 or anti-Jak2 antibodies. Western blots (WB) were probed
with anti-phosphotyrosine (p-Tyr) or anti-Jak1 or anti-Jak2 antibodies.
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phosphorylation of STAT1 (Samuel, 2001; Stark et al., 1998). This
prediction contradicts the unhindered tyrosine phosphorylation of
STAT1 in MV-infected cells following IFN-γ stimulation as shown in
both Fig. 3A (top right panel) and Fig. 3B (bottom panel).
In an effort to reconcile this apparent contradiction, we sought
to examine the tyrosine phosphorylation proﬁles of Jak1 and Jak2
following IFN-γ stimulation of MV-infected CCD-922Sk ﬁbroblasts.
Jak1 is also pre-associated with IFNGR1 while Jak2 is pre-associated
with IFNGR2 (Randall and Goodbourn, 2008; Stark et al., 1998).
We observed that IFN-γ stimulation resulted in potent tyrosine
phosphorylation of Jak1 (Fig. 6C, top panel, lane 3) and Jak2 (Fig.
6C, third panel, lane 3) in mock-infected cells. In contrast, IFN-γ-
induced tyrosine phosphorylation of Jak1 (Fig. 6C, top panel, lane 4)
or Jak2 (Fig. 6C, third panel, lane 4) was not signiﬁcantly
suppressed by MV infection. Thus, these differential tyrosine
phosphorylation patterns of Jak1 induced by IFN-αC versus IFN-γ
in MV-infected cells suggest that the selective inhibition of tyrosine
phosphorylation of Tyk2 is the pivotal evasion strategy employed by
MV to disrupt the type I IFN-Jak-STAT signaling in primary human
ﬁbroblasts.
Discussion
Poxviruses are a family of large cytoplasmic DNA viruses that have
considerable medical and veterinary importance (Esposito and
Fenner, 2001). Although a number of antiviral measures are involved
in the host defense against poxvirus infection, type I IFN remains to be
one of the key innate factors during poxviral pathogenesis, species
barriers and cellular tropism (McFadden, 2005; Seet et al., 2003;
Takaoka and Yanai, 2006; Wang et al., 2004). Hence, uncovering the
countermeasures employed by poxviruses against the infected host
IFN response is essential to better understand poxvirus pathobiology.
In this study, we have shown that MV infection selectively disrupts the
type I IFN-Jak-STAT signaling cascade in primary human ﬁbroblasts.
This occurs mainly through the functional blockade of Tyk2, a key
Janus kinase upstream of STAT1 and STAT2, thereby preventing a type
I IFN-transduced signal from inducing the expression of antiviral ISGs.
This evasion strategy is not only different from the poxviral IFN decoy
receptors aimed at antagonizing host IFN ligands extracellularly
(Randall and Goodbourn, 2008), but is also distinct from the pre-
viously reported poxviral phosphatase that has been shown todephosphorylate STAT1 and STAT2 intracellularly (Mann et al.,
2008; Najarro et al., 2001).
Tyk2 is the ﬁrst member of the Janus kinase family to be char-
acterized as a prototypic non-receptor tyrosine kinase (Firmbach-
Kraft et al., 1990). The criticality of Tyk2 in type I IFN signal trans-
duction was initially demonstrated in human ﬁbroblast cell lines by
genetic complementation (Muller et al., 1993; Velazquez et al., 1992).
More recently, it has been further demonstrated that type I IFN fails
completely to activate STAT1 and STAT2 in the human cells derived
from a patient genetically deﬁcient in Tyk2 (Minegishi et al., 2006).
In contrast, two independent groups have shown that the murine
cells derived from Tyk2 knockout mice nevertheless retain the
capability of initiating tyrosine phosphorylation of STAT1 and STAT2
in responding to type I IFN, particularly at a relatively high
concentration (Karaghiosoff et al., 2000; Shimoda et al., 2000).
Taken together, these studies clearly indicate that the requirement
for Tyk2 in the type I IFN signaling cascade is more stringent in
human than in mouse cells. In this report, we have observed that in
primary human ﬁbroblasts, MV infection abrogated the tyrosine
phosphorylation of not only the upstream kinase Tyk2, but also
downstream STAT1 and STAT2 following IFN-αC stimulation. Taken
collectively, our data reveals that Tyk2 is the functionally essential
signaling molecule targeted by MV to antagonize type I IFN-Jak-STAT
signaling in virus-infected primary human ﬁbroblasts.
Notably, although only a moderate inhibition of IFN-γ-induced
tyrosine phosphorylation of Jak1 was observed following MV infec-
tion, IFN-αC-induced tyrosine phosphorylation of Jak1 was substan-
tially suppressed. This is an interesting observation given that Jak1 is a
common kinase used by both type I and type II IFN pathways (Rodig
et al., 1998; Stark et al., 1998). In the type II IFN pathway, binding of
IFN-γ to its cell surface receptor brings IFNGR1-associated Jak1 and
IFNGR2-associated Jak2 into close proximity, resulting in Jak2
activation. The activated Jak2 then triggers tyrosine phosphorylation
of Jak1 (Stark et al., 1998; Takaoka and Yanai, 2006). According to this
canonical model, it is not immediately clear why MV-invoked
inhibition of Tyk2 should affect IFN-γ-induced activation of Jak1. Of
relevance in this regard, a similar reduction in IFN-γ-induced tyrosine
phosphorylation of Jak1 was found in the cells genetically deﬁcient
in Tyk2 gene (Karaghiosoff et al., 2000). Currently, the exact me-
chanism(s), as towhy in some cell systems Tyk2 affects IFN-γ-induced
activation of Jak1, still remain elusive. Nevertheless, since broad cross-
talk between type I and type II IFN signaling components have been
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superstructure (Karaghiosoff et al., 2000; Schroder et al., 2004;
Takaoka et al., 2000), the partial reduction in IFN-γ-induced tyrosine
phosphorylation of Jak1 in MV-infected primary human ﬁbroblasts
might imply that MV-blocked Tyk2 would present some hindrance for
Jak2 to maximally activate Jak1. Further experimental investigation
will be needed to test this hypothesis.
On the other hand, type I IFN binding to its cell surface receptor
juxtaposes IFNAR1-associated Tyk2 and IFNAR2-associated Jak1,
causing Tyk2 tyrosine phosphorylation through activated Jak1 (Gauzzi
et al., 1996). The activated Tyk2 then cross-phosphorylates Jak1, fur-
ther activating each other in turn for signal ampliﬁcation (Stark et al.,
1998). Based on these considerations, it seems highly plausible that
the vigorous blockade we observed of IFN-αC-induced Jak1 tyrosine
phosphorylation is due to the lack of the Tyk2-driven cross-
phosphorylation of Jak1 resulting from MV-caused blockade to Tyk2
activation.
Our discovery that MV speciﬁcally abolishes IFN-αC-induced Tyk2
activation suggests the following scenarios that might explain MV's
inhibitory effects. Firstly, we have observed that the expression of IFN-
α receptor per se or IFN binding to the cell surface is not affected by
MV infection in primary human ﬁbroblasts. Secondly, a higher
concentration of type I IFN did not show any saturating effect on the
reversal of Tyk2 activation in MV-infected cells (data not shown).
Thirdly, Tyk2 is known to phosphorylate the IFNAR1 subunit ﬁrst
before it can activate STAT1 and STAT2 (Stark et al., 1998). In this
regard, we have not detected any IFNAR1 tyrosine phosphorylation
following IFN-αC stimulation in MV-infected cells (data not shown).
Fourthly, we have found that UV-inactivated MV fails to block IFN-αC-
induced tyrosine phosphorylation of Tyk2 (data not shown). Fifthly,
the deletion of the gene for the sole predicted type I IFN decoy
receptor M135R has no effect on MV-mediated inhibition of Jak-STAT1
activation in response to type I IFN stimulation. On the basis of these
results, we speculate that Tyk2 is the prime target byMV infection and
that viral protein(s) expressed during MV infection interacts directly
or indirectly with Tyk2, consequently hindering Tyk2 from being
activated upon type I IFN binding to its cell surface IFN-α receptor.
Alternatively, MV infection in primary human ﬁbroblasts may trigger
the expression or activation of a cellular inhibitor of Tyk2, thereby
preventing Tyk2 from being accessible to the type I IFN-transduced
stimuli. Such robust inhibitors as suppressor of cytokine signaling
(SOCS) have been increasingly recognized as important negative
regulators for the Jak-STAT signaling system under various physiolo-
gical conditions (Yoshimura et al., 2007). In particular, it has been
recently shown that tumor-induced SOCS3 physically binds to Tyk2,
thereby suppressing type I IFN signal transduction in mouse models
(Zeng et al., 2008). Further studies will be required to dissect the
above potential scenarios.
Vaccinia virus VH1 phosphatase inhibits the IFN-Jak-STAT signal
transduction rapidly by speciﬁc targeting of STAT1 tyrosine phosphor-
ylation induced by either type I or type II IFN in a viral gene
expression-independent manner. In particular, VH1 phosphatase does
not inhibit the tyrosine phosphorylation of the upstream Janus
kinases (Mann et al., 2008; Najarro et al., 2001). In contrast, MV-
mediated disruption of the IFN-Jak-STAT signaling pathway requires
viral gene expression. Signiﬁcantly, MV infection mainly blocks the
Janus kinase Tyk2 in the context of the type I IFN signaling cascade,
but has no signiﬁcant inhibitory effect on type II IFN-induced tyrosine
phosphorylation of Jak1 and Jak2. On the other hand, MV I1L and
vaccinia virus VH1 phosphatases do share a common essential feature
in that I1L and VH1 are both critically required for a normal productive
infection of MV and vaccinia virus, respectively (Liu et al., 1995;
Mossman et al., 1995a). Thus, our results suggest that, except for being
central to the poxviral life, the superimposed anti-host functions of
poxviral phosphatases may vary markedly among individual pox-
viruses. This is of interest considering the fact that VH1 homologousgenes are highly conserved among the poxvirus family members
(Mossman et al., 1995a; Najarro et al., 2001).
Poxviruses are adept at secreting various viral IFN decoy
receptors to inactivate host IFN (Randall and Goodbourn, 2008;
Seet et al., 2003). Interestingly, vaccinia virus-encoded type I IFN
decoy receptors can bind IFN-α/β from broad species including cow
and human (Alcami et al., 2000). In contrast, MV-encoded type II
IFN binding proteins are rabbit-speciﬁc. As such, the IFN-γ receptor
mimetic encoded by an early MV gene M-T7 binds only to rabbit
IFN-γ, but not to mouse or human IFN-γ (Mossman et al., 1995b). In
this study, we have conﬁrmed that no viral IFN decoy receptors
encoded by MV interfere with the action or the binding of either
human IFN-αC or IFN-γ (data not shown) to the cell surface IFN
receptors of CCD-922Sk ﬁbroblasts. Of further functional relevance
in this regard, we have noted that MV infection in primary rabbit
embryo ﬁbroblasts (pREFs) are resistant to rabbit type I IFN
(Supplementary Fig. 1A, top panel) whereas VSV infection in
pREFs are highly sensitive to the antiviral state induced by rabbit
type I IFN (Supplementary Fig. 1A, bottom panel). By analogy,
human type I IFN fails to effectively contain MV infection
(Supplementary Fig. 1B, top panel) but is able to fully control VSV
infection in primary human ﬁbroblasts (Supplementary Fig. 1B,
bottom panel). Thus, from an evolutionary point of view, these
analogies suggest that MV's ability to antagonize type I IFN signaling
may play an important role in the modulation of a host cell's
permissiveness to MV infection outside of the rabbit species.
The natural host range of MV is restricted to the rabbit species,
such that even live MV injection cannot cause clinical disease in
humans (Fenner and Ratcliffe, 1965). Therefore, deconstructing why
MV can disrupt the IFN-Jak-STAT signaling in human cells will provide
essential information for the development of MV as a novel tumor-
killing agent in oncolytic virotherapy (Lun et al., 2005; Lun et al., 2007;
Woo et al., 2008;Wu et al., 2008). Furthermore, these studies will also
shed light on the dynamics of viral tropism at the cellular, tissue and
organismal levels in general when a virus encounters a non-
evolutionary host (McFadden, 2005; Virgin, 2007).
Materials and methods
Cell culture, IFN, primary antibodies and viral infections
Primary human skin ﬁbroblasts CCD-922Sk (kindly provided by Dr.
Scot Roberts) were maintained in MEM with 10% FBS, penicillin
(100 u/ml) and streptomycin (100 μg/ml). For the preparation of
primary rabbit embryo ﬁbroblasts (pREFs), 21-day-old New Zealand
White rabbit embryos were employed according to the standard 3T3
protocol (Todaro and Green, 1963). Human IFN-αC and IFN-γ were
obtained from PBL Biomedical Laboratories. Rabbit type I IFN was
prepared in primary rabbit kidney cells as previously described
(Mozes and Vilcek, 1981). Immunodetecting primary antibodies were
from the following sources: phospho-STAT1 (Tyr-701) antibody:
Upstate Biotechnology; Jak1, Jak2, Tyk2, STAT1α, STAT2, IFN-α,
IFNAR1, IFNAR2, USF2 and phosphotyrosine antibodies: Santa Cruz
Biotechnology; β-actin antibody: Sigma; anti-MV M-T7 antibody was
previously described (Mossman et al., 1996). MV (Lausanne strain)
with or without lacZ gene inserted at an innocuous intergenic site
under the control of a late viral promoter was previously described
(Opgenorth et al., 1992). UV-inactivated MV was prepared utilizing a
Stratagene Stratalinker. The preparation of GFP-tagged wild type MV
(MV-gfp) or the MV with knockout of M135R gene (MV-135KO-gfp)
was previously described (Barrett et al., 2007). When indicated for the
MV infection in the presence of AraC (Sigma), the drug was used at
40 μg/ml. MV infections were conducted at a multiplicity of infection
(MOI) of 5 unless speciﬁed otherwise. Vesicular stomatitis virus
expressing GFP (VSV-gfp) was described previously (Stojdl et al.,
2003).
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For SuperArray analysis, CCD-922Sk ﬁbroblasts grown in 25 cm2
ﬂasks were stimulated with IFN-αC at 200 U/ml for 4 h. Total cellular
RNA was isolated using the RNA puriﬁcation kit from SABiosciences.
Five micrograms of total RNAs from each sample were reverse trans-
cribed and cDNA probes were generated by biotin-16-dUTP (Roche)
incorporation employing the AmpoLabeling-LPR kit (SABiosciences)
according to the product instructions. The labeled cDNA probes were
hybridized to the nylon membranes of GEArray Q Series SuperArray
(HS-054, SABiosciences) according to the manufacturer's protocol.
The SuperArray format contained a total of 96 genes representing
various signaling components and target molecules related to human
IFN-α/β response pathways. The membrane-bound cDNA probes
were detected using an alkaline phosphatase-conjugated streptavidin
and subsequently visualized by CDP-Star chemiluminescence sub-
strate (SABiosciences). The hybridization signals were recorded on X-
ray ﬁlms and digitalized using an Epson densitometer scanner. Image
analysis and data acquisition were carried out through the web-based
integrated GEArray Expression Analysis Suite provided by SABios-
ciences. The IFN-αC-induced genes in the experimental group were
considered to be of biological importance when the induction change
was greater than 1.5-fold cut-off criteria compared to the control
group.
RT-PCR
CCD-922Sk ﬁbroblasts grown in 25 cm2 ﬂasks were infected with
MV for 6 h. TheMV-infected cells were then stimulatedwith IFN-αC at
200 U/ml for 4 h. Subsequently, the cells were lysed following various
treatments as speciﬁed and total cellular RNA was isolated using the
RNeasy kit (Qiagen). Reverse transcription was performed using
Superscript reverse transcriptase (Gibco BRL). Primer sequences for
human MxA, OAS and GAPDH as well as RT-PCR conditions were
described (Fujii et al., 1999; Stewart et al., 2006).
Immunoﬂuorescence microscopy
For immunoﬂuorescent staining, CCD-922Sk ﬁbroblasts were
grown on coverslips. After infection with MV for 6 h, the infected
ﬁbroblasts were stimulated for 30 min with either IFN-αC or IFN-γ at
200 U/ml as speciﬁed. Subsequently, the cells were ﬁxed in cold
methanol for 10 min, washed in PBS and blocked in 5% normal goat
serum for 50 min. For the double immunoﬂuorescent staining of
STAT1 and MV early gene product M-T7, mouse monoclonal anti-
STAT1 and rabbit anti-MV M-T7 antibodies were applied at room
temperature for 1 h followed by a 50-min secondary detection with
Texas Red-conjugated goat anti-mouse IgG and FITC-conjugated goat
anti-rabbit IgG, respectively. For the double immunoﬂuorescent
staining of phospho-STAT1 (Tyr-701) and M-T7, rabbit anti-phos-
pho-STAT1 and mouse monoclonal anti-MV M-T7 antibodies were
applied at room temperature for 1 h followed by a 50-min secondary
detection with Texas Red-conjugated goat anti-rabbit IgG and FITC-
conjugated goat anti-mouse IgG, respectively. Subsequently, the
nuclear DNA of immunostained cells were counterstained with DAPI
(4′,6-diamidino-2-phenylindole, dihydrochloride, Molecular Probes)
according to the product speciﬁcation. The secondary antibody
conjugates were from Jackson ImmunoResearch Laboratories. The
ﬂuorescence images were taken with a Leica DMIRE2 microscope.
Immunoprecipitation and Western blotting
For tyrosine phosphorylated forms of STAT1, STAT2, Tyk2, Jak1 and
Jak2, CCD-922Sk ﬁbroblasts were maintained in 25 cm2 ﬂasks. After
infection with MV for 6 h, the infected ﬁbroblasts were stimulated for
15 or 30 min with either IFN-αC or IFN-γ at 200 U/ml as speciﬁed.Subsequently, whole cell extracts were prepared using the commer-
cial formula of RIPA lysis buffer as recommended in the immunopre-
cipitation protocol by Santa Cruz Biotechnology. The whole cell
extracts were cleared for 1 h at 4 °C with control IgG and protein-A/G-
Sepharose (Santa Cruz Biotechnology). Subsequent immunoprecipita-
tions were performed with the indicated antibodies at 4 °C overnight.
The immune complexes were precipitated with protein-A/G-Sephar-
ose and then rendered for electrophoresis on 7.5% SDS-polyacrylamide
gels. After the electrophoretically separated immunoprecipitates were
transferred to Hybond-C nitrocellulose (Amersham Pharmacia Bio-
tech), Western blotting analysis was then performed with respective
primary antibodies. Thereafter, bands were visualized utilizing
secondary HRP-conjugated antibodies and ECL system (NEN Life
Science Products).
Detection of cell surface IFN-α receptor IFNAR1 and IFNAR2 and
IFN-αC binding
CCD-922Sk ﬁbroblasts were ﬁrst infected with MV for 6 h and then
washed thoroughly with cold PBS (pH 8.0). For biotinylation of the cell
surface protein molecules, the washed cells were incubated with
Sulfo-NHS-Biotin (Pierce) in PBS for 30 min according to the product
speciﬁcations. Thereafter, the whole cell extracts were prepared and
the immunoprecipitates achieved with anti-IFNAR1 or anti-IFNAR2
antibodies were subjected to electrophoresis and subsequentWestern
blotting with HRP-streptavidin conjugate. For the IFN-αC binding
experiment, IFN-αC was ﬁrst biotinylated as described (Plett et al.,
2000). Then, the biotinylated IFN-αC was incubated with both mock
and MV-infected CCD-922Sk cells at 4 °C for 1 h. After washing in PBS,
the cell extracts were prepared and the immunoprecipitates obtained
with an anti-IFN-α antibody were rendered to Western blotting with
HRP-streptavidin conjugate following SDS-PAGE.
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